Loading...
XSHE300138
Market cap542mUSD
Jan 10, Last price  
8.09CNY
1D
-1.70%
1Q
-9.20%
Jan 2017
-13.02%
IPO
0.86%
Name

Chenguang Biotech Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300138 chart
P/E
8.29
P/S
0.58
EPS
0.98
Div Yield, %
0.00%
Shrs. gr., 5y
0.74%
Rev. gr., 5y
17.54%
Revenues
6.87b
+9.14%
152,468,285319,565,685414,023,777584,062,5171,071,253,750951,326,9321,186,224,7031,207,179,7021,267,629,1952,140,846,6802,772,135,8133,063,440,5753,265,232,8153,912,935,2824,873,610,3946,295,872,7806,871,515,007
Net income
480m
+10.53%
11,696,34038,496,00948,762,01163,525,86375,031,06558,894,80710,494,01222,381,38368,862,53492,474,001142,829,814145,283,057193,572,517267,741,336351,514,428434,033,194479,722,222
CFO
-511m
L
09,061,52727,233,290082,180,83600272,955,41100000529,412,71363,899,957734,807,406-510,907,208
Dividend
Jun 13, 20240.13 CNY/sh
Earnings
May 09, 2025

Profile

ChenGuang Biotech Group Co., Ltd. develops and produces natural colors, spice extracts and essential oils, nutritional and pharmaceutical extracts, and oils and protein. The company offers natural colors, including paprika oleoresin, marigold oleoresin, and turmeric; spice extracts and essential oils, such as capsicum oleoresin, sichuan pepper oil, pepper oleoresin, ginger extract, and cumin oil; lutein, lycopene, grape seed extract, curcumin, inulin, stevioside, and green coffee bean extracts; and grape seed oil, walnut oil, safflower seed oil, flaxseed oil, cottonseed oil, natural lutein, and dephenolized cottonseed protein products. Its products are primarily used in food, cosmetics, baking, beverages, health care, and feed industries. The company operates in Europe; the Americas; Australia; China, Russia, Japan, Korea, and other countries in Asia; and Africa. ChenGuang Biotech Group Co., Ltd. was incorporated in 2000 and is based in Quzhou, China.
URL
https://www.cn-cg.com/
IPO date
Nov 05, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,871,515
9.14%
6,295,873
29.18%
Cost of revenue
6,245,296
5,647,923
Unusual Expense (Income)
NOPBT
626,219
647,950
NOPBT Margin
9.11%
10.29%
Operating Taxes
61,645
65,671
Tax Rate
9.84%
10.14%
NOPAT
564,574
582,279
Net income
479,722
10.53%
434,033
23.48%
Dividends
(69,261)
Dividend yield
0.73%
Proceeds from repurchase of equity
(95,836)
BB yield
1.34%
Debt
Debt current
2,258,613
2,066,256
Long-term debt
872,571
778,008
Deferred revenue
117,725
93,694
Other long-term liabilities
52,227
68,085
Net debt
727,711
1,605,361
Cash flow
Cash from operating activities
(510,907)
734,807
CAPEX
(189,199)
Cash from investing activities
(525,829)
Cash from financing activities
1,296,816
39,045
FCF
710,954
157,021
Balance
Cash
2,290,522
1,164,237
Long term investments
112,952
74,666
Excess cash
2,059,897
924,110
Stockholders' equity
2,480,145
2,184,533
Invested Capital
5,110,014
5,243,638
ROIC
10.91%
11.70%
ROCE
8.71%
10.48%
EV
Common stock shares outstanding
532,020
532,752
Price
13.43
-24.25%
17.73
6.17%
Market cap
7,145,025
-24.36%
9,445,696
7.02%
EV
7,934,521
11,100,321
EBITDA
779,047
793,272
EV/EBITDA
10.18
13.99
Interest
83,507
67,207
Interest/NOPBT
13.34%
10.37%